Boston Scientific Corporation's everolimus-eluting coronary stent system [Promus] can be marketed in the 25 countries of the EU

Source: Inpharma, Volume 1, Number 1560, 2006-10-21 , pp. 23-23(1)

Publisher: Adis International

Keywords: Boston-Scientific-Corporation; Coronary-artery-restenosis, prevention; Coronary-stenting; Development-status; Drug-eluting-stents; Everolimus, therapeutic use; Product-approvals

Document Type: Short communication

Publication date: 2006-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers